在高风险的急性肺栓塞中,用reteplase进行全身血栓溶解的结果
相关实验视频
Updated: May 13, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
20.6K
Leila Bigdelu1, Mahla Deldar2, Asal Yadollahi3
1Vascular and Endovascular Surgery Research Center, 37552 Mashhad University of Medical Sciences , Mashhad, Iran.
Journal of basic and clinical physiology and pharmacology
|April 14, 2025
概括
雷特普拉斯通过改善血液动力学和症状,有效治疗高风险的肺栓塞 (PE). 这项研究发现 reteplase 是PE患者的安全和有效的血栓溶解药物选择,没有严重的出血并发症.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 血栓溶解疗法 血栓溶解疗法
背景情况:
- 高危肺栓塞 (PE) 呈现出血液动力学不稳定性和高死亡率.
- 目前的指导方针建议在PE中使用阿尔特来治疗系统性血栓溶解.
- 对于患有高风险PE的患者来说,立即再输血至关重要.
研究的目的:
- 评估在高风险PE患者中使用reteplase进行全身血栓溶解的疗效和安全性.
- 评估 reteplase 对血液动力学参数和临床症状的影响.
- 为了确定与这群人群中的 reteplase 治疗相关的并发症率.
主要方法:
- 对30名患有高风险急性PE的患者进行了回顾性观察研究.
- 所有患者都呈现出阻塞性休克.
- 治疗包括30分钟间隔的两次10U玻尿酸剂,然后是肝素.
主要成果:
- 雷特普拉斯改善了缩血压,呼吸困难,呼吸暂停和咳.
- 氧和度 (SpO2) 在治疗后显著增加.
- 右心室扩张得到改善,肺动脉压力下降,没有严重出血或死亡.
结论:
- 以两次玻尿酸注射的方式使用的雷特普拉斯对急性高风险PE有效.
- 该疗法显示出较低的重大出血并发症风险.
- 雷特普拉斯为高风险PE患者的全身血栓溶解提供了一个可行的替代方案.
相关概念视频
Clot Retraction and Fibrinolysis
2.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.9K
Flail Chest-II
142
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
142
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
108
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
108
Pneumothorax-II
107
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
107
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
93
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
93
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
116
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
116

